PROTAC SOS1 degrader-5 is a small molecule designed as a targeted protein degradation agent, specifically targeting the SOS1 protein, which plays a crucial role in RAS signaling pathways. This compound belongs to the class of PROTACs (Proteolysis Targeting Chimeras), which harness the cell's ubiquitin-proteasome system to selectively degrade specific proteins. The characteristics of PROTAC SOS1 degrader-5 include its ability to bind to both the target protein (SOS1) and an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of SOS1. This mechanism is particularly valuable in cancer research, as SOS1 is implicated in various malignancies due to its role in promoting RAS activity. The compound's efficacy, selectivity, and pharmacokinetic properties are critical for its potential therapeutic applications. Additionally, its chemical structure likely includes functional groups that enhance solubility and bioavailability, making it suitable for in vivo studies. Overall, PROTAC SOS1 degrader-5 represents a promising approach in the development of targeted cancer therapies.

PROTAC SOS1 degrader-5

2836273-61-9: PROTAC SOS1 degrader-5 is a small molecule designed as a targeted protein degradation agent, specifically targeting the SOS1 protein, which plays a crucial role in RAS signaling pathways. This compound belongs to the class of PROTACs (Proteolysis Targeting Chimeras), which harness the cell's ubiquitin-proteasome system to selectively degrade specific proteins. The characteristics of PROTAC SOS1 degrader-5 include its ability to bind to both the target protein (SOS1) and an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of SOS1. This mechanism is particularly valuable in cancer research, as SOS1 is implicated in various malignancies due to its role in promoting RAS activity. The compound's efficacy, selectivity, and pharmacokinetic properties are critical for its potential therapeutic applications. Additionally, its chemical structure likely includes functional groups that enhance solubility and bioavailability, making it suitable for in vivo studies. Overall, PROTAC SOS1 degrader-5 represents a promising approach in the development of targeted cancer therapies.

<p>PROTAC SOS1 degrader-5 (compound 4) serves as an effective degrader of PROTAC SOS1, exhibiting a DC50 of 13 nM. It robustly suppresses the proliferation of NCI-H358 cells, with an IC50 value of 5 nM [1].</p>

CAS 2836273-61-9

PROTAC SOS1 degrader-5

PROTAC SOS1 degrader-5

Ref: TM-T87268